Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Study Shows Why Leukemia Returns in Some Children

Published: Thursday, February 28, 2013
Last Updated: Thursday, February 28, 2013
Bookmark and Share
With sophisticated new DNA techniques, a team of researchers has found, for the first time, why many children with a type of leukemia suffer a relapse.

The researchers found that about 20 percent of children with T-cell acute lymphoblastic leukemia (T-ALL) who experience a relapse harbor mutations that activate NT5C2, an enzyme that inactivates an important chemotherapy drug, 6-mercaptopurine (6-MP).

The discovery may soon lead to improved treatment for patients. “The most immediate thing to do now is to develop diagnostic tools,” said Ferrando, professor of Pediatrics and of Pathology & Cell Biology in the Herbert Irving Comprehensive Cancer Center.

“With diagnostic tools, we could monitor for this mutation and if we see it, these patients should probably receive a different drug.”

About one in five children with T-ALL will suffer a relapse, and despite intensive chemotherapy, most of these children will die from the disease.

Based on his findings, Ferrando said relapsed patients with the mutated enzyme could be switched to a new drug, nelarabine, that’s very similar to 6-MP. The researchers found that even though the two drugs act similarly, they are different chemically, and nelarabine is not affected by the mutated enzyme.

Full findings of the research were published Feb. 3 in Nature Medicine.

The mutated enzyme also was discovered independently in a New York University study of patients with the B-cell form of ALL.

In a New York Genome Center article about both studies, the leader of the NYU study, William Carroll, MD, said

“I think for those of us who treat leukemia, it is a really dramatic finding. Access to [patient] samples and new next-generation sequencing [give us a way] to really understand the blueprint of relapse and to develop specific therapies. We can individualize treatment.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Celiac Disease Risk Linked to Non-coding RNA
Suggests factors outside of protein-coding genes play a role in celiac disease.
Friday, April 01, 2016
New Way to Identify Brain Tumor Aggressiveness
Looking at a brain tumor’s epigenetic signature may help guide therapy.
Friday, January 29, 2016
Test Could Identify Which Prostate Cancers Require Treatment
3-gene biomarker gauges tumor’s aggressiveness.
Thursday, September 12, 2013
Columbia Licenses Novel 3-D Organ and Tumor Segmentation Software to Varian Medical Systems
Allows for more precise and efficient planning and monitoring of cancer treatment.
Friday, May 17, 2013
Two Treatments for Retinitis Pigmentosa Move Closer to Clinical Trials
One treatment involves skin-derived induced pluripotent stem (iPS) cell grafts, the other gene therapy.
Friday, December 21, 2012
Columbia Awarded One of First NCI “Provocative Questions” Grants
Timothy H. Bestor, PhD, an epigenetics researcher and professor of genetics and development at CUMC, was selected for his proposal, “Methylation Suicide in Cancer”.
Friday, September 21, 2012
DNA Repair: How Chromosomes Find Each Other
Study found that after a double-strand break in DNA, the mobility of both the broken segment and other, unbroken, chromosomes is greatly increased.
Wednesday, June 06, 2012
Scientific News
Revealing the Genetic Causes of Bowel Cancer
A landmark study has given the most detailed picture yet of the genetics of bowel cancer — the UK's fourth most common cancer.
Self-Assembling Protein Shell for Drug Delivery
Made-to-order nano-cages open possibilities of shipping cargo into living cells or fashioning small chemical reactors.
Fighting Resistant Blood Cancer Cells
Biologists present new findings on chronic myeloid leukemia and possible therapeutic approaches.
Tumor Cells Develop Predictable Characteristics
Scientists have discovered that cancer cells at the edge of a tumor that are close to the surrounding environment are predictably different from the cells within the interior of the tumor.
Guided Chemotherapy Missiles
Latching chemotherapy drugs onto proteins that seek out tumors could provide a new way of treating tumors in the brain or with limited blood supply that are hard to reach with traditional chemotherapy.
Solutions for Biotherapeutic Characterization
Innovation to speed the routine.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Biomarkers That Could Help Give Cancer Patients Better Survival Estimates Discovered
UCLA research may also help scientists suppress dangerous genetic sequences.
Body’s Own Gene Editing System Generates Leukemia Stem Cells
Inhibiting the editing enzyme may provide a new therapeutic approach for blood cancers.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!